abstract |
The present invention includes: anxiolytic disorders; conditions that require treatment of damaged mammalian neural tissue; conditions that can be treated through administration of neurotrophic factors; neurological disorders; or obesity; obesity-related disorders Novel GlyT2 inhibitory compounds that are effective in modulating, treating or preventing are provided. |